Literature DB >> 26974507

Preparation of Scaffold-Free Tissue-Engineered Constructs Derived from Human Synovial Mesenchymal Stem Cells Under Low Oxygen Tension Enhances Their Chondrogenic Differentiation Capacity.

Yukihiko Yasui1, Ryota Chijimatsu1, David A Hart2, Kota Koizumi1, Norihiko Sugita1, Kazunori Shimomura1, Akira Myoui3, Hideki Yoshikawa1, Norimasa Nakamura1,4,5.   

Abstract

Low oxygen tension (LOT) has been reported to promote chondrogenic differentiation and prevent cellular senescence of stem cells. Therefore, the introduction of LOT conditions into conventional tissue engineering processes could further improve the potential of the constructs generated for cartilage repair. The purpose of this study was to elucidate the feasibility of LOT preparation on the chondrogenic differentiation of a scaffold-free tissue-engineered construct (TEC) derived from synovial mesenchymal stem cells (MSCs), construct whose feasibility for cartilage repair has been demonstrated in previous preclinical and clinical studies. Culture of MSCs under LOT conditions prevented cellular senescence and promoted the proliferative capacity of human synovial MSCs. In addition, TEC prepared from human synovial MSCs under LOT conditions (5% O2; LOT-TEC) showed superior in vitro chondrogenic differentiation capacity compared to that prepared under the usual 20% O2 (normal oxygen tension [NOT]; NOT-TEC), with elevated glycosaminoglycan production and elevated levels of chondrogenic marker gene expression. Notably, LOT-TEC differentiated into a hyaline-like cartilaginous tissue of approximately 1 cm in diameter without the detectable presence of fibrous tissue, while conventional NOT-TEC differentiated into a mixture of hyaline-like and fibrocartilaginous tissues. This is the first demonstration of in vitro development of a hyaline-like cartilaginous tissue of an implantable size to chondral lesion that was derived from human MSCs without the use of an exogenous scaffold. The manipulation of oxygen tension is a safe procedure with low cost and, thus, may be a clinically relevant option to improve the quality of TEC-mediated cartilage repair.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26974507     DOI: 10.1089/ten.tea.2015.0458

Source DB:  PubMed          Journal:  Tissue Eng Part A        ISSN: 1937-3341            Impact factor:   3.845


  11 in total

Review 1.  Scaffold-free, stem cell-based cartilage repair.

Authors:  Yukihiko Yasui; Wataru Ando; Kazunori Shimomura; Kota Koizumi; Chijimatsu Ryota; Shuichi Hamamoto; Masato Kobayashi; Hideki Yoshikawa; Norimasa Nakamura
Journal:  J Clin Orthop Trauma       Date:  2016-06-28

2.  Impact of dexamethasone concentration on cartilage tissue formation from human synovial derived stem cells in vitro.

Authors:  Ryota Chijimatsu; Masato Kobayashi; Kosuke Ebina; Toru Iwahashi; Yosuke Okuno; Makoto Hirao; Atsunori Fukuhara; Norimasa Nakamura; Hideki Yoshikawa
Journal:  Cytotechnology       Date:  2018-01-19       Impact factor: 2.058

3.  IGF-1 Gene Transfer to Human Synovial MSCs Promotes Their Chondrogenic Differentiation Potential without Induction of the Hypertrophic Phenotype.

Authors:  Yasutoshi Ikeda; Morito Sakaue; Ryota Chijimatsu; David A Hart; Hidenori Otsubo; Kazunori Shimomura; Henning Madry; Tomoyuki Suzuki; Hideki Yoshikawa; Toshihiko Yamashita; Norimasa Nakamura
Journal:  Stem Cells Int       Date:  2017-06-27       Impact factor: 5.443

4.  Characterization of Mesenchymal Stem Cell-Like Cells Derived From Human iPSCs via Neural Crest Development and Their Application for Osteochondral Repair.

Authors:  Ryota Chijimatsu; Makoto Ikeya; Yukihiko Yasui; Yasutoshi Ikeda; Kosuke Ebina; Yu Moriguchi; Kazunori Shimomura; David A Hart; Yoshikawa Hideki; Nakamura Norimasa
Journal:  Stem Cells Int       Date:  2017-05-10       Impact factor: 5.443

5.  Respective stemness and chondrogenic potential of mesenchymal stem cells isolated from human bone marrow, synovial membrane, and synovial fluid.

Authors:  Paul Neybecker; Christel Henrionnet; Elise Pape; Laurent Grossin; Didier Mainard; Laurent Galois; Damien Loeuille; Pierre Gillet; Astrid Pinzano
Journal:  Stem Cell Res Ther       Date:  2020-07-25       Impact factor: 6.832

6.  Combination of polyetherketoneketone scaffold and human mesenchymal stem cells from temporomandibular joint synovial fluid enhances bone regeneration.

Authors:  Yi Lin; Mayumi Umebayashi; Mohamed-Nur Abdallah; Guoying Dong; Michael G Roskies; Yaoyao Fiona Zhao; Monzur Murshed; Zhiguang Zhang; Simon D Tran
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

Review 7.  Human Organ-Specific 3D Cancer Models Produced by the Stromal Self-Assembly Method of Tissue Engineering for the Study of Solid Tumors.

Authors:  Vincent Roy; Brice Magne; Maude Vaillancourt-Audet; Mathieu Blais; Stéphane Chabaud; Emil Grammond; Léo Piquet; Julie Fradette; Isabelle Laverdière; Véronique J Moulin; Solange Landreville; Lucie Germain; François A Auger; François Gros-Louis; Stéphane Bolduc
Journal:  Biomed Res Int       Date:  2020-04-13       Impact factor: 3.411

Review 8.  Improved therapeutics of modified mesenchymal stem cells: an update.

Authors:  Dickson Kofi Wiredu Ocansey; Bing Pei; Yongmin Yan; Hui Qian; Xu Zhang; Wenrong Xu; Fei Mao
Journal:  J Transl Med       Date:  2020-01-30       Impact factor: 5.531

9.  Promoting Effect of Basic Fibroblast Growth Factor in Synovial Mesenchymal Stem Cell-Based Cartilage Regeneration.

Authors:  Gensuke Okamura; Kosuke Ebina; Makoto Hirao; Ryota Chijimatsu; Yasukazu Yonetani; Yuki Etani; Akira Miyama; Kenji Takami; Atsushi Goshima; Hideki Yoshikawa; Takuya Ishimoto; Takayoshi Nakano; Masayuki Hamada; Takashi Kanamoto; Ken Nakata
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

10.  In vitro and in vivo potentialities for cartilage repair from human advanced knee osteoarthritis synovial fluid-derived mesenchymal stem cells.

Authors:  Paul Neybecker; Christel Henrionnet; Elise Pape; Didier Mainard; Laurent Galois; Damien Loeuille; Pierre Gillet; Astrid Pinzano
Journal:  Stem Cell Res Ther       Date:  2018-11-28       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.